Oncostatin M in the anti-inflammatory response

被引:0
|
作者
Wahl, AF [1 ]
Wallace, PM [1 ]
机构
[1] Seattle Genet Inc, Bothell, WA 98021 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Oncostatin M (OM) is a pleiotropic cytokine of the interleukin b family, whose in vivo properties and physiological function remain in dispute and poorly defined. These in vivo studies strongly suggest that OM is anabolic, promoting wound healing and bone formation, and antiinflammatory. In models of inflammation OM is produced late in the cytokine response and protects from lipopolysaccharide (LPS)-induced toxicities, promoting the re-establishment of homoeostasis by cooperating with proinflammatory cytokines and acute phase molecules to alter and attenuate the inflammatory response. Administration of OM inhibited bacterial LPS-induced production of tumour necrosis factor a and septic lethality in a dose dependent manner. Consistent with these findings, in animal models of chronic inflammatory disease OM potently suppressed inflammation and tissue destruction in murine models of rheumatoid arthritis and multiple sclerosis. T cell function and antibody production were not impaired by OM treatment. Taken together, these data indicate that the activities of this cytokine in vivo are anti-inflammatory without concordant immunosuppression.
引用
收藏
页码:III75 / III80
页数:6
相关论文
共 50 条
  • [1] Characterization of a backbone cleavage product of BMS-196854 (Oncostatin M), a recombinant anti-inflammatory cytokine
    Zhao, F
    Stein, DJ
    Paborji, M
    Cash, PW
    Root, BJ
    Wei, ZP
    Knupp, CJ
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2001, 6 (02) : 255 - 261
  • [2] Anti-inflammatory response and cardiopulmonary bypass
    Denizot, Yves
    Nathan, Nathalie
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2010, 38 (06) : 818 - 818
  • [3] Compensatory anti-inflammatory response syndrome
    Adib-Conquy, Minou
    Cavaillon, Jean-Marc
    THROMBOSIS AND HAEMOSTASIS, 2009, 101 (01) : 36 - 47
  • [4] Pieces of the IVIG anti-inflammatory response
    Maria Papatriantafyllou
    Nature Reviews Immunology, 2011, 11 : 499 - 499
  • [5] Immature anti-inflammatory response in neonates
    Schultz, C
    Temming, P
    Bucsky, P
    Göpel, W
    Strunk, T
    Härtel, C
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 135 (01): : 130 - 136
  • [6] Oncostatin M Primes Macrophages for an Enhanced Pro-Inflammatory Response
    Khadaroo, Rachel G.
    Young, Pang Y.
    Mian, Qaasim N.
    Young, Jeremy C.
    Compston, Catherine A.
    Mueller, Thomas F.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2014, 219 (03) : S42 - S42
  • [7] Host inflammatory and anti-inflammatory response during sepsis
    Adib-Conquy, M.
    Cavaillon, J. -M.
    PATHOLOGIE BIOLOGIE, 2012, 60 (05): : 306 - 313
  • [8] Regulation of inflammatory responses by oncostatin M
    Wallace, PM
    MacMaster, JF
    Rouleau, KA
    Brown, TJ
    Loy, JK
    Donaldson, KL
    Wahl, AF
    JOURNAL OF IMMUNOLOGY, 1999, 162 (09): : 5547 - 5555
  • [9] Interstitial cystitis: Response to anti-inflammatory treatment
    Gorton, E
    Doyle, M
    Sutherst, JR
    INTERNATIONAL CONTINENCE SOCIETY - 26TH ANNUAL MEETING, 1996, : 23 - 27
  • [10] NONSTEROIDAL ANTI-INFLAMMATORY DRUG RISKS RESPONSE
    Thornhill, Martin H.
    Suda, Katie J.
    Durkin, Michael J.
    Lockhart, Peter B.
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2020, 151 (01): : 5 - 6